Technical Analysis for NBY - NovaBay Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade D 1.13 9.71% 0.10
NBY closed up 9.71 percent on Friday, January 18, 2019, on 1.62 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical NBY trend table...

Date Alert Name Type % Chg
Jan 18 Crossed Above 50 DMA Bullish 0.00%
Jan 18 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Weak + Overbought Other 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 50 DMA Resistance Bearish 9.71%
Jan 17 180 Bearish Setup Bearish Swing Setup 9.71%
Jan 17 Calm After Storm Range Contraction 9.71%
Jan 17 Stochastic Reached Overbought Strength 9.71%

Older signals for NBY ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

NovaBay Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the development of various product candidates for the therapeutic needs of the anti-infective market. The company operates in four segments: Dermatology, Ophthalmology, Urology, and Wound Care. It has categories of compounds, Aganocides and NeutroPhase. The company's Aganocide compounds comprise NVC-422 that is in Phase IIb clinical study for the treatment of adenoviral conjunctivitis, a contagious viral eye infection; impetigo, a highly contagious skin infection; and urinary catheter blockage and encrustation, and associated urinary tract infections. Its NeutroPhase product is a hypochlorous acid solution, has approved for the treatment of patients who suffer from chronic non-healing wounds, such as pressure, venous stasis, and diabetic ulcers. The company has collaboration and license agreement with Galderma S.A. to develop and commercialize its Aganocide compounds, which covers acne, impetigo, and other dermatological conditions. It also has strategic marketing agreement with Pioneer Pharma Co., Ltd. to market its pharmaceutical products in China and other Asian markets. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is based in Emeryville, California.
Is NBY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.0
52 Week Low 0.71
Average Volume 13,860
200-Day Moving Average 1.9797
50-Day Moving Average 1.1023
20-Day Moving Average 0.991
10-Day Moving Average 1.045
Average True Range 0.124
ADX 18.16
+DI 19.2759
-DI 24.7208
Chandelier Exit (Long, 3 ATRs ) 0.828
Chandelier Exit (Short, 3 ATRs ) 1.082
Upper Bollinger Band 1.1802
Lower Bollinger Band 0.8018
Percent B (%b) 0.87
BandWidth 38.183653
MACD Line -0.015
MACD Signal Line -0.0366
MACD Histogram 0.0216
Fundamentals Value
Market Cap 17.3 Million
Num Shares 15.3 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -1.43
Price-to-Sales 4.39
Price-to-Book 20.95
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.31
Resistance 3 (R3) 1.29 1.21 1.28
Resistance 2 (R2) 1.21 1.16 1.22 1.27
Resistance 1 (R1) 1.17 1.14 1.19 1.19 1.26
Pivot Point 1.09 1.09 1.10 1.10 1.09
Support 1 (S1) 1.05 1.04 1.07 1.07 1.00
Support 2 (S2) 0.97 1.02 0.98 0.99
Support 3 (S3) 0.93 0.97 0.98
Support 4 (S4) 0.95